Bayer to cut internal drug R&D work, axing hundreds of researchers while looking to partners as it unveils plan to slash 12,000 jobs
Bayer is pushing ahead with plans to restructure its drug R&D business and cut 900 research staffers as part of a broad plan to slash a total of 12,000 employees in a worldwide revamp.
Details on the changes in R&D — something that’s been rumored to be in the works for months — are slim, with no word about which projects are threatened. Their statement notes 900 jobs are being cut in pharma R&D with another 350 jobs slashed at a German factor VIII production plant. The emphasis now will shift in drug R&D, reducing in-house work while looking to external partners to carry more of the load.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.